DOP035 Beclomethasone dipropionaat is effective for microscopic colitis: results of an open-label multicentre study (COLCO)

Abstract

Background: Microscopic colitis (MC: collagenous (CC) or lymphocytic colitis (LC)) is characterised by chronic watery diarrhoea and possibly fecal incontinence. Budesonide has proven effective for MC: the two commercially available preparations are released in the ileum. Beclomethasone dipropionaat (Clipper) is a synthetic corticosteroid with topical colonic release. We hereby report the first series of MC patients treated with open label beclomethasone. Methods: Prospectively collected data of 23 patients with CC or LC from six centres were retrospectively analysed. Inclusion criteria were: confirmed diagnosis of MC and symptomatic disease (DAI >= 21, i.e. >=21 loose stools over 7 days). Treatment consisted of beclomethasone 10 mg/day for 4 weeks, followed by 5 mg/day for 4 weeks. Patients filled out a Bristol stool scale diary at baseline, Week 4 and Week 8. At Week 12, patients were contacted again by telephone for follow-up. The primary endpoint is the proportion of patients in remission (DAI